Meningitis b vaccine booster shows promise in kids
NCT ID NCT01621945
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a fourth dose of the MenBVac vaccine boosts protection against meningitis B in children. Researchers measured immune responses in 120 children before and after the booster. The goal was to see if the vaccine maintains protective antibody levels over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MenBVac vaccine
- What this could lead to
- If successful, this could confirm that a fourth dose of MenBVac provides lasting protection against meningitis B in children.
- What could go wrong
- This is a completed Phase 3 trial, but results may not apply to all children or other meningitis strains. The vaccine may not provide long-term immunity for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEISSERIA MENINGITIDIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Maison Du Département
Neufchâtel-en-Bray, 76270, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.